Monitoring HIV pre-exposure prophylaxis (PrEP) uptake in Australia: Issue #7, October 2022

HIV pre-exposure prophylaxis (PrEP) was listed on the Pharmaceutical Benefits Scheme (PBS) on 1 April 2018. The PBS subsidises the cost of PrEP for people eligible for Medicare in Australia. The cost to the patient for 30 pills as of June 2022 was $42.50 for general patients and$6.80 for concession card holders. This report uses data from every PBS-subsidised PrEP prescription that was dispensed in Australia between 1 April 2018 and 30 June 2022. The deidentified data incorporate unique codes for linking individuals. Variables include patient details (age, sex, postcode of residence, concession status), information about dispensing (date of dispensing, quantity dispensed), and prescriber details (postcode, specialty). Data are presented on the total number of people who have ever initiated PBSsubsidised PrEP, as well as the number of people dispensed PrEP within each quarter, and within the past 12 months. These data are disaggregated by age, and by state or territory of patient residence, and presented as population rates. This report also includes a section investigating the effect of COVID-19-related lockdowns on monthly dispensing data by jurisdiction

Monitoring HIV pre-exposure prophylaxis (PrEP) uptake in Australia. Issue #4, June 2021

Description: This report uses data extracted from every PrEP prescription supplied in Australia through the Pharmaceutical Benefits Scheme (PBS) between 1 April 2018 and 31 March 2021. Data are presented on the total number of people who have ever initiated PBS-subsidised PrEP, as well as the number of people dispensed PrEP within each quarter. These data are disaggregated by age, and by state or territory of patient residence. This report also includes a section investigating the effect of COVID-19-related lockdowns on presents monthly dispensing data by jurisdiction since COVID-19-related lockdowns began

Monitoring HIV pre-exposure prophylaxis (PrEP) uptake in Australia. Issue #5, January 2022

Description This report uses data extracted from every PrEP prescription supplied in Australia through the Pharmaceutical Benefits Scheme (PBS) between 1 April 2018 and 30 September 2021. Data are presented on the total number of people who have ever initiated PBS-subsidised PrEP, as well as the number of people dispensed PrEP within each quarter. These data are disaggregated by age, and by state or territory of patient residence. This report also includes a section investigating the effect of COVID-19-related lockdowns on presents monthly dispensing data by jurisdiction since COVID-19-related lockdowns began

Monitoring HIV pre-exposure prophylaxis (PrEP) uptake in Australia: Issue #8, May 2023

HIV pre-exposure prophylaxis (PrEP) was listed on the Pharmaceutical Benefits Scheme (PBS) on 1 April 2018. The PBS subsidises the cost of PrEP for people eligible for Medicare in Australia. The cost to the patient for 30 pills as of May 2023 was $30.00 for general patients and$7.30 for concession card holders. This report uses data from every PBS-subsidised PrEP prescription that was dispensed in Australia between 1 April 2018 and 31 December 2022. The de-identified data incorporate unique codes for linking individuals. Variables include patient details (age, sex, postcode of residence, concession status), information about dispensing (date of dispensing, quantity dispensed), and prescriber details (postcode, specialty). Data are presented on the total number of people who have ever initiated PBS-subsidised PrEP, as well as the number of people dispensed PrEP within each quarter, and within the past 12 months. These data are disaggregated by age, and by state or territory of patient residence, and presented as population rates. This report also includes a section investigating the effect of COVID-19-related lockdowns on monthly dispensing data by jurisdiction